Showing 1 - 20 results of 105 for search '"Drugs for Neglected Diseases Initiative"', query time: 0.74s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study by Victor Kande Betu Ku Mesu, DPH, Wilfried Mutombo Kalonji, MD, Clélia Bardonneau, MSc, Olaf Valverde Mordt, MSc, Digas Ngolo Tete, MPH, Séverine Blesson, MSc, François Simon, MSc, Sophie Delhomme, MSc, Sonja Bernhard, PhD, Hélène Mahenzi Mbembo, MD, Christian Mpia Moke, MD, Steven Lumeya Vuvu, MMed, Junior Mudji E'kitiak, MD, Felix Akwaso Masa, MD, Melchias Mukendi Ilunga, MD, Dieudonné Mpoyi Muamba Nzambi, MD, Tim Mayala Malu, MD, Serge Kapongo Tshilumbwa, MD, Franck Botalema Bolengi, MD, Mathieu Nkieri Matsho, MD, Crispin Lumbala, MPH, Bruno Scherrer, PhD, Nathalie Strub-Wourgaft, MD, Antoine Tarral, MD

    Published 2021-07-01
    “…Funding: Through the Drugs for Neglected Diseases initiative: the Bill & Melinda Gates Foundation, the Republic and Canton of Geneva (Switzerland), the Dutch Ministry of Foreign Affairs (also known as DGIS; Netherlands), the Norwegian Agency for Development Cooperation (also known as Norad; Norway), the Federal Ministry of Education and Research (also known as BMBF) through KfW (Germany), the Brian Mercer Charitable Trust (UK), and other private foundations and individuals from the HAT campaign. …”
    Get full text
    Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Drug discovery and development for neglected diseases: the DNDi model by Eric Chatelain, Jean-Robert Ioset

    Published 2011-03-01
    “…Eric Chatelain, Jean-Robert IosetDrugs for Neglected Diseases Initiative (DNDi), Geneva, SwitzerlandAbstract: New models of drug discovery have been developed to overcome the lack of modern and effective drugs for neglected diseases such as human African trypanosomiasis (HAT; sleeping sickness), leishmaniasis, and Chagas disease, which have no financial viability for the pharmaceutical industry. …”
    Get full text
    Article
  18. 18
  19. 19
  20. 20